Related references
Note: Only part of the references are listed.Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells
Hsiao-Hsuan Kuo et al.
IMMUNITY (2018)
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells
Szu-Han Huang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo
Carolina Garrido et al.
JOURNAL OF VIROLOGY (2018)
Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation
Lillian B. Cohn et al.
NATURE MEDICINE (2018)
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits &ITEx Vivo&IT Lipopolysaccharide-Induced Inflammatory Responses
Christel Rothe Brinkmann et al.
MSPHERE (2018)
Targeting histone deacetylases in T-cell lymphoma
Alison J. Moskowitz et al.
LEUKEMIA & LYMPHOMA (2017)
Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity
Alyssa R. Martin et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy
Allison S. Thomas et al.
PLOS PATHOGENS (2017)
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
Julia A. Sung et al.
EBIOMEDICINE (2017)
The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+T cells
Abena K. Kwaa et al.
PLOS ONE (2017)
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal
Guoxin Wu et al.
JCI INSIGHT (2017)
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy
Talia M. Mota et al.
AIDS (2017)
Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape
Ross A. Pollack et al.
CELL HOST & MICROBE (2017)
Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells
R. Brad Jones et al.
BIOMATERIALS (2017)
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption
Jonathan Z. Li et al.
AIDS (2016)
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors
Hongbing Yang et al.
MOLECULAR THERAPY (2016)
Latency reversal and viral clearance to cure HIV-1
David M. Margolis et al.
SCIENCE (2016)
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
R. Brad Jones et al.
PLOS PATHOGENS (2016)
HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
Carolina Garrido et al.
FRONTIERS IN IMMUNOLOGY (2016)
The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
Victoria E. Walker-Sperling et al.
EBIOMEDICINE (2016)
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function (vol 6, 30749, 2016)
G. Clutton et al.
SCIENTIFIC REPORTS (2016)
Targeting NF-κB Signaling with Protein Kinase C Agonists As an Emerging Strategy for Combating HIV Latency
Guochun Jiang et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir
Julia A. Sung et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Post-treatment control of HIV infection
Jessica M. Conway et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation
Guochun Jiang et al.
PLOS PATHOGENS (2015)
Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection
Natalia Soriano-Sarabia et al.
PLOS PATHOGENS (2015)
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Sogaard et al.
PLOS PATHOGENS (2015)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
Giovanna Bossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Emerging strategies to deplete the HIV reservoir
Nancie M. Archin et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
Nancy M. Archin et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
HIV Control Is Mediated in Part by CD8+ T-Cell Targeting of Specific Epitopes
Florencia Pereyra et al.
JOURNAL OF VIROLOGY (2014)
A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
Elizabeth R. Plimack et al.
ONCOLOGIST (2014)
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H. Elliott et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
Richard Brad Jones et al.
PLOS PATHOGENS (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
A Single Peptide-Major Histocompatibility Complex Ligand Triggers Digital Cytokine Secretion in CD4+ T Cells
Jun Huang et al.
IMMUNITY (2013)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+T Cells from Aviremic Patients
Celsa A. Spina et al.
PLOS PATHOGENS (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma
Sasha Stephen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Michael J. Kelly-Sell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study
Robert J. Morgan et al.
INVESTIGATIONAL NEW DRUGS (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control
Beatriz Mothe et al.
PLOS ONE (2012)
Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency
Matthew J. Pace et al.
PLOS PATHOGENS (2012)
Towards an HIV cure: a global scientific strategy
Steven G. Deeks
NATURE REVIEWS IMMUNOLOGY (2012)
HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
Sharon R. Lewin et al.
AIDS (2011)
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1
Dan Zhao et al.
CELLULAR IMMUNOLOGY (2011)
Inflammatory cytokines as a third signal for T cell activation
Julie M. Curtsinger et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Anna C. Pavlick et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Mechanisms of costimulation
Arlene H. Sharpe
IMMUNOLOGICAL REVIEWS (2009)
HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition
Toshiyuki Miura et al.
JOURNAL OF VIROLOGY (2009)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
R. Brad Jones et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Protein kinase C signalling in leukemia
Amanda J. Redig et al.
LEUKEMIA & LYMPHOMA (2008)
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication
Arne Schneidewind et al.
JOURNAL OF VIROLOGY (2007)
Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection
Cheryl L. Day et al.
JOURNAL OF VIROLOGY (2007)
PD-1 up-regulation is correlated with HIV-specific memory CD8(+) T-cell exhaustion in typical progressors, but not in long-terrn nonprogressors
Ji-Yuan Zhang et al.
BLOOD (2007)
Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
V. M. Richon
BRITISH JOURNAL OF CANCER (2006)
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction (vol 12, 1198, 2006)
L. Trautmann et al.
NATURE MEDICINE (2006)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
IFN-γ and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways
Huifen Li et al.
JOURNAL OF IMMUNOLOGY (2006)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it
DH Hamer
CURRENT HIV RESEARCH (2004)
Memory CD8 T-cell differentiation during viral infection
EJ Wherry et al.
JOURNAL OF VIROLOGY (2004)
T cell killing does not require the formation of a stable mature immunological synapse (vol 5, pg 524, 2004)
MA Purbhoo et al.
NATURE IMMUNOLOGY (2004)
T-cell-antigen recognition and the immunological synapse
JB Huppa et al.
NATURE REVIEWS IMMUNOLOGY (2003)
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
S Madhusudan et al.
BRITISH JOURNAL OF CANCER (2003)
Direct observation of ligand recognition by T cells
DJ Irvine et al.
NATURE (2002)
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection
A Oxenius et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+T cell depletion
RME Van Praag et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2001)
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
SA Migueles et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
L Ruiz et al.
AIDS (2000)
Share Paper
